 JERSEY CITY, N.J., June 11, 2021 GLOBE NEWSWIRE -- SCYNEXIS, Inc. NASDAQ: SCYX, a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant fungal infections, today announced that Marco Taglietti, M.D., President and Chief Executive Officer of SCYNEXIS, will present at the BIO Digital International Convention to be held virtually from June 10 11 and 14 18, 2021. The Company presentation will highlight BREXAFEMME ibrexafungerp tablets, in addition to other late-stage clinical trials evaluating ibrexafungerp in the community setting for recurrent vaginal yeast infections, and as a treatment for life threatening fungal infections, including Candida auris, in the hospital setting. The presentation is now available to registered attendees. 